Clinical trial
Combination Therapy With Oral 9-Nitrocamptothecin & Oral Etoposide
NCT00006047 · H. Lee Moffitt Cancer Center and Research Institute, Other · Completed
Key facts
| NCT number | NCT00006047 |
|---|---|
| Title | Combination Therapy With Oral 9-Nitrocamptothecin & Oral Etoposide |
| Official title | Phase I Study of Combination Therapy With Oral 9-Nitrocamptothecin and Oral Etoposide |
| Lead sponsor | H. Lee Moffitt Cancer Center and Research Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH Astex Pharmaceuticals, Inc. Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | Oral Etoposide, Oral 9-Nitrocamptothecin |
| Enrollment | 44 |
| Start date | Jun 1, 2000 |
| Primary completion | Feb 1, 2003 |
| Completion | Feb 1, 2003 |
| First posted | Feb 12, 2004 |
| Last update posted | Sep 26, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: